Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Subscribe here to receive future editions. Most people quit a highly popular class of weight loss and diabetes drugs called GLP-1s within a year of starting them, several studies have shown.

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Nearly 2 in 3 people who sought to lose weight quit popular weight loss and diabetes drugs such as Ozempic or Victoza within one year, according to a new study. About 65% of those without diabetes ...

Drugs like Ozempic® and Mounjaro® have become blockbuster drugs as of late, making headlines not only for their powerful weight loss effects, but also for their potential to help other conditions – as ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...

A new AP-NORC poll reveals that while most Americans support weight-loss drugs like Ozempic and Wegovy for adults with obesity, they are divided on their use for teens. About half of adults favor ...

Weight loss drugs have surged in popularity, with millions turning to medications like Ozempic and Wegovy in hopes of shedding excess weight and managing diabetes. These drugs, classified as GLP-1 ...